As reported on Inside Precision Medicine, a novel optogenetics-based treatment may offer a new path toward restoring some visual function in people with advanced retinitis pigmentosa (RP), according to findings from a small early-stage clinical study. Researchers reported that the therapy was generally well tolerated and produced measurable improvements in visual performance for several participants when paired with specialized visual stimulation goggles.
Addressing a Major Unmet Need
Retinitis pigmentosa is a group of inherited retinal disorders that affect more than 1.5 million people worldwide. The disease causes progressive degeneration of photoreceptor cells, ultimately leading to severe vision loss or blindness. Because mutations in more than 100 different genes can cause RP, developing gene-specific treatments for every form of the disease remains a significant challenge.
Investigators sought a more universal strategy that could restore visual function regardless of the underlying genetic mutation. Their approach, described in The New England Journal of Medicine, uses optogenetic technology to make surviving retinal cells responsive to light after the eye’s native photoreceptors have been lost.
How the Therapy Works
The treatment involves a single injection of an adeno-associated viral vector into the eye. The vector delivers instructions for producing ChrimsonR, a light-sensitive protein that responds to amber-colored light.
Patients then use specially engineered goggles equipped with a camera and portable processor. The system captures visual information from the environment, converts it into light patterns optimized for ChrimsonR activation, and projects those signals back onto the retina. This process is designed to stimulate genetically modified retinal cells and generate visual information that can be transmitted to the brain.
Early Clinical Results
The study enrolled 10 adults with advanced RP-related blindness, with an average age of 55 years. Each participant received the treatment in their poorer-seeing eye.
The primary goal of the trial was to assess safety. Researchers documented 34 adverse events among nine participants. Most were mild or moderate and included temporary inflammation and short-term increases in intraocular pressure. One participant experienced a brief blockage of the central retinal artery immediately after injection, but the event resolved within minutes following treatment.
Despite the study’s small size, investigators observed encouraging signs of efficacy. Seven participants demonstrated improved sensitivity to light following treatment, and six achieved improvements considered clinically meaningful.
Functional Gains Without Full Vision Restoration
The therapy did not restore normal sight or reading ability. However, several participants gained the ability to better detect, localize, and reach toward objects while using the goggles. For example, some were more successful in identifying features such as doorways and determining their position in space.
Researchers also noted that participants who spent more time training with the visual stimulation system generally performed better on object-detection tasks. The finding suggests that rehabilitation and adaptation may play a significant role in maximizing benefits from optogenetic treatments.
Evidence of Visual Processing in the Brain
Using electroencephalography (EEG), investigators found signs that visual signals generated by the treatment were reaching and being processed by the visual cortex. This provides objective evidence that the modified retinal cells were transmitting information through the visual pathway.
Notably, four participants showed sustained improvements across multiple real-world visual tasks during follow-up periods extending up to five years.
Looking Ahead
The findings suggest that even after profound vision loss, the visual system may retain the capacity to interpret new sensory input when appropriate neural pathways remain intact. While larger studies are needed to confirm efficacy and long-term safety, the results highlight the potential of optogenetic therapy as a mutation-independent treatment strategy for RP.
Researchers also believe the approach could eventually be explored in other blinding conditions characterized by photoreceptor loss but preservation of downstream retinal cells, including retinal ganglion cells. If successful, such therapies could broaden treatment options for patients whose vision cannot be restored through conventional gene-specific interventions.
